PPARG and metabolic dysfunction-associated steatotic liver disease: Furthermore, additional investigations have demonstrated that lncRNA H19 exerts a hepatoprotective effect by directly modulating the miR-130a/PPARγ axis, thereby attenuating hepatic lipid accumulation and potentially contributing to the pathogenesis of NAFLD.[13] The expression of lncRNA H19 in the liver of db/db mice was downregulated, leading to an increased binding of p53 on the FoxO1 promoter and subsequently promoting FoxO1 transcription.